Lobbying disclosures · Lobbying report
NBIX: third_quarter 2026 lobbying report
Issues related to implementation of the Inflation Reduction Act, P.L. 117-169, including potential changes to the structure of and reimbursement for Medicare Part D. H.R. 946 - Orphan Cures Act H.R. 1492 / S. 832 - Ensuring Pathways to Innovative Cures (EPIC) Act Issues related to drug pricing Regulatory and legislative healthcare issues related to pharmaceutical development, approval, reimbursement, and patient access. Issues related to the screening, diagnosis, and treatment of Tardive Dyskinesia. Issues related to telehealth including the Telemental Health Care Access Act of 2023, H.R. 3432
Follow NBIX- Became public
- Oct 20, 2026, 12:10 PM EDT
- Event / period date
- Not stated
- Collected
- Nov 11, 2026, 3:17 PM EST
Why this is connected
Exact legal-name match: NEUROCRINE BIOSCIENCES INC (https://www.sec.gov/Archives/edgar/data/914475/).
Reported lobbying amounts
Expenses: $940,000.00
These are different reporting measures. They are not added together or treated as spending on one particular bill.
Source evidence
Read the source excerpt or record
{"url":"https://lda.gov/api/v1/filings/8966530c-a2ac-40d2-a2e1-9467066bb811/","filing_uuid":"8966530c-a2ac-40d2-a2e1-9467066bb811","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/8966530c-a2ac-40d2-a2e1-9467066bb811/print/","filing_document_content_type":"text/html","income":null,"expenses":"940000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Aaron Cohen","dt_posted":"2026-10-20T12:10:31-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"6027 Edgewood Bend Court","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"San Diego","registrant_state":"CA","registrant_zip":"92130","registrant":{"id":401105485,"url":"https://lda.gov/api/v1/registrants/401105485/","house_registrant_id":null,"name":"NEUROCRINE BIOSCIENCES, INC","description":"Drug discovery and development","address_1":"6027 Edgewood Bend Court","address_2":null,"address_3":null,"address_4":null,"city":"San Diego","state":"CA","state_display":"California","zip":"92130","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"FREDERICK DOMBO","contact_telephone":"+1 202-887-1485","dt_updated":"2026-07-30T11:04:36.757386-04:00"},"client":{"id":203759,"url":"https://lda.gov/api/v1/clients/203759/","client_id":12,"name":"NEUROCRINE BIOSCIENCES, INC","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"CA","state_display":"California","country":"US","country_display":"United States of America","ppb_state":"CA","ppb_state_display":"California","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2019-09-01"},"lobbying_activities":[{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Issues related to implementation of the Inflation Reduction Act, P.L. 117-169, including potential changes to the structure of and reimbursement for Medicare Part D. H.R. 946 - Orphan Cures Act H.R. 1492 / S. 832 - Ensuring Pathways to Innovative Cures (EPIC) Act Issues related to drug pricing","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":90662,"prefix":null,"prefix_display":null,"first_name":"STEVEN","nickname":null,"middle_name":null,"last_name":"SILVESTRI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":104952,"prefix":null,"prefix_display":null,"first_name":"VALARIE","nickname":null,"middle_name":null,"last_name":"MOLAISON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142523,"prefix":null,"prefix_display":null,"first_name":"AARON","nickname":null,"middle_name":null,"last_name":"COHEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":12,"name":"White House Office"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Regulatory and legislative healthcare issues related to pharmaceutical development, approval, reimbursement, and patient access. Issues related to the screening, diagnosis, and treatment of Tardive Dyskinesia. Issues related to telehealth including the Telemental Health Care Access Act of 2023, H.R. 3432, and the Telehealth Modernization Act of 2024, H.R. 7623. Issues related to the Rare Pediatric Priority Review Voucher Program.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":90662,"prefix":null,"prefix_display":null,"first_name":"STEVEN","nickname":null,"middle_name":null,"last_name":"SILVESTRI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":104952,"prefix":null,"prefix_display":null,"first_name":"VALARIE","nickname":null,"middle_name":null,"last_name":"MOLAISON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142523,"prefix":null,"prefix_display":null,"first_name":"AARON","nickname":null,"middle_name":null,"last_name":"COHEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Support appropriations report language and funding to encourage additional support from the Department of Health and Human Services and the Department of Veterans Affairs for physical conditions associated with mental illness, such as Tardive Dyskinesia.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":90662,"prefix":null,"prefix_display":null,"first_name":"STEVEN","nickname":null,"middle_name":null,"last_name":"SILVESTRI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":104952,"prefix":null,"prefix_display":null,"first_name":"VALARIE","nickname":null,"middle_name":null,"last_name":"MOLAISON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142523,"prefix":null,"prefix_display":null,"first_name":"AARON","nickname":null,"middle_name":null,"last_name":"COHEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Issues related to the Research and Development (R&D) tax credit including the Tax Relief for American Families and Workers Act of 2024, H.R. 7024. Issues related to the Orphan Drug Tax Credit.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":90662,"prefix":null,"prefix_display":null,"first_name":"STEVEN","nickname":null,"middle_name":null,"last_name":"SILVESTRI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":104952,"prefix":null,"prefix_display":null,"first_name":"VALARIE","nickname":null,"middle_name":null,"last_name":"MOLAISON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142523,"prefix":null,"prefix_display":null,"first_name":"AARON","nickname":null,"middle_name":null,"last_name":"COHEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}Congressional trading in NBIX
These disclosures provide context. Their presence does not establish a link between a trader and the event.
- Aug 13, 2025$1K–$15K
Rep. Lisa C. McClain (R-MI-9)
Sold (partial) Neurocrine Biosciences NBIX
$1K–$15K · Traded Jun 17, 2025 · disclosed Aug 13, 2025 · Spouse · filed 57 days later
- Aug 13, 2025$1K–$15K
Rep. Lisa C. McClain (R-MI-9)
Bought Neurocrine Biosciences NBIX
$1K–$15K · Traded Jun 11, 2025 · disclosed Aug 13, 2025 · Spouse · filed 63 days later
- Jun 22, 2023$15K–$50K
Rep. Michael T. McCaul (R-TX-10)
Sold Neurocrine Biosciences NBIX
$15K–$50K · Traded May 2, 2023 · disclosed Jun 22, 2023 · filed 51 days later
- Jun 22, 2023$15K–$50K
Rep. Michael T. McCaul (R-TX-10)
Sold Neurocrine Biosciences NBIX
$15K–$50K · Traded May 2, 2023 · disclosed Jun 22, 2023 · Spouse · filed 51 days later
Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.